On Tuesday this week Labor successfully established the Senate Inquiry into the use of the Quinoline anti-malarial drugs Mefloquine and Tafenoquine in the Australian Defence Force.

This Senate Inquiry will provide a transparent and thorough investigation into the concerns of Quinoline anti-malarial drugs in the ADF.
 
With concerns from the serving and ex-service community about the side effects of some anti-malarials, this Senate Inquiry will allow our ex-service personnel, medical professionals and peak bodies to speak firsthand of their experience and knowledge of Mefloquine and Tafenoquine.

The Coalition, Greens and Senate Crossbench have shown their support today for Labor’s push to have this Senate Inquiry established and Labor looks forward to working with the Senate during this process.  
 
The Senate Inquiry is open for public submissions and will provide dates for upcoming public hearings with a final report due back to the Senate on Monday 17 September, 2018.  
 
Labor looks forward to the outcomes of this important inquiry.
  
The Terms of Reference for the Senate Inquiry into the use of the Quinoline anti-malarial drugs Mefloquine and Tafenoquine in the Australian Defence Force.are below;
 
The use of the Quinoline anti-malarial drugs Mefloquine and Tafenoquine in the Australian Defence Force with particular reference to:

1. Current and past policies and practices for prescribing quinolone anti-malarial drugs to ADF personnel
2. Current and past policies and practices for identifying and reporting adverse drug reactions from Quinoline anti-malarial drugs among ADF personnel
3. The nature and extent of any adverse health effects of those who have taken Mefloquine/Tafenoquine on serving and former ADF personnel
4. Support available for partners, carers and families of personnel who experience any adverse health effects of Quinoline anti-malarial drugs
5. A comparison of international evidence/literature available on the impact of Quinoline anti-malarials
6. How other governments have responded to claims regarding Quinoline anti-malarials
7. Any other related matters